((自动化翻译由路透提供，请见免责声明 ))
10月29日 - ** 药物开发商Coya Therapeutics 股价盘前上涨7.8%至10.98美元
** 该公司称其试验性阿尔茨海默氏症药物 (link) 是安全的，并在一项小型中期试验中提高了阿尔茨海默氏症患者体内一种免疫细胞的水平
** 抗体药物 COYA 301 属于 IL-2 治疗类药物，旨在增强抑制免疫反应的调节性 T 细胞的功能
** 使用该药物进行每月一次的治疗后，认知功能略有改善，大脑和脊髓液中与疾病相关的β-淀粉样蛋白水平也有所提高
** 截至上次收盘，股价累计上涨 37.5
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.